The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV Infection
Abstract
OBJECTIVE: Uncontrolled studies have suggested a benefit, after treatment discontinuation, of initiating highly active antiretroviral therapy (HAART) during primary human immunodeficiency virus (HIV) infection. We assessed whether initiation of HAART within 2 weeks of (acute treatment) or between 2 weeks and 6 months after (early treatment) HIV seroconversion was associated with improvements in the viral load and the CD4+ T cell count after discontinuation of treatment in an observational cohort. METHODS: Subjects from the multicenter Acute Infection and Early Disease Research Program cohort were enrolled in the present study within 6 months of HIV seroconversion and self-selected whether to initiate HAART. Subjects who received acute (n=13) or early (n=45) treatment received HAART for at least 12 weeks and then subsequently stopped treatment, whereas untreated subjects (n=337) declined treatment. HIV RNA levels and CD4+ T cell counts at 24, 48, and 72 weeks after treatment cessation in the 2 treatment groups were compared with those noted in the untreated group during the same periods of observation after enrollment. RESULTS: The acute treatment group had lower mean HIV RNA levels at 24 weeks without therapy (-0.48 log(10) copies/mL [95% confidence interval {CI}, -0.82 to -0.13 log(10) copies/mL]) and higher mean CD4+ T cell counts (112 cells/ mu L [95% CI, 20-205 cells/ microL]), compared with the untreated group at 24 weeks. The differences in the laboratory values for the acute treatment group versus the untreated group at 72 weeks without therapy were as follows: for the HIV RNA level, -0.35 log(10) copies/mL (95% CI, -0.91 to 0.21 log(10) copies/mL) and, for the CD4 T+ cell count, 112 cells/ microL (95% CI, -15 to 213 cells/ microL). The early treatment group had lower HIV RNA levels at 24 weeks than did the untreated group, but differences were no longer apparent by week 48; CD4+ T cell counts were higher in the early treatment group at week 24 (116 cells/ microL [95% CI, 75-157 cells/ microL]) and week 72 (70 cells/ microL [95% CI, 2-138 cells/ microL]). CONCLUSIONS: Initiation of HAART within 2 weeks of antibody seroconversion was associated with viral load and CD4+ T cell count benefits for 24 weeks after termination of HAART, with there being trends toward a longer-term benefit. Later initiation of HAART was associated with a persistent but decreasing CD4+ T cell count benefit and a loss of the viral load benefit by week 72 after discontinuation of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mixed-Effects Models in S and S-PLUS
(2001) · Technometrics · doi:10.1198/tech.2001.s574 · Cited by 9,278
Clinical and epidemiologic features of primary HIV infection.
Schacker, T., Collier, A. C., Hughes, J., Shea, T., & Corey, L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-4-199608150-00001 · Cited by 703 · cited 1×
“The typical symptoms of primary HIV infection and the role of HIV RNA testing in diagnosis have been well described elsewhere [21-25].”
BackgroundSelf-citation
Cited by
Sáez-Cirión, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., Potard, V., Versmisse, P., Melard, A., Prazuck, T., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003211 · Cited by 1,011
Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy
Le, T., Wright, E. J., Smith, D. M., He, W., Catano, G., Okulicz, J. F., Young, J. A., Clark, R. A., Richman, D. D., Little, S. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110187 · Cited by 355
Self-citationHIV-1 transcription and latency: an update
Van Lint, C., Bouchat, S., & Marcello, A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-67 · Cited by 338
Laboratory testing for the diagnosis of HIV infection : updated recommendations
(U.S.), C. F. D. C. A. P., Bernard M., B., Association of Public Health Laboratorie, S. Michele, O., Laura G., W., Berry, B., Barbara G., W., Kelly E., W., & Michael A., P. (2014) · doi:10.15620/cdc.23447 · Cited by 305
HIV rebounds from latently infected cells, rather than from continuing low-level replication
Joos, B., Fischer, M., Kuster, H., Pillai, S. K., Wong, J. K., Böni, J., Hirschel, B., Weber, R., Trkola, A., Günthard, H. F., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804192105 · Cited by 294
Metadata
- Authors
- Hecht, F. M., Wang, L., Collier, A., Little, S., Markowitz, M., Margolick, J., Kilby, J. M., Daar, E., Conway, B., Holte, S., & AIEDRP Network
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-15
- Volume
- 194
- Issue
- 6
- Pages
- 725-733
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2170838597
- Cited by
- 172
- References
- 2
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV Infection. https://app.cochat.ai/papers/10.1086/506616
- The paper
- Hecht, F. M., Wang, L., Collier, A., Little, S., Markowitz, M., Margolick, J., Kilby, J. M., Daar, E., Conway, B., Holte, S., & AIEDRP Network. (2006). A Multicenter Observational Study of the Potential Benefits of Initiating Combination Antiretroviral Therapy during Acute HIV Infection. The Journal of Infectious Diseases. https://doi.org/10.1086/506616
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.